The increasing cases of cardiovascular diseases such as deep vein thrombosis & pulmonary embolism are expected to spur demand for heparin in the forthcoming. The global heparin market size is expected to reach USD 11.43 billion by 2027, exhibiting a CAGR of 3.9% during the forecast period. years, states Fortune Business Insights, in a report, titled “Heparin Market Size, Share & Industry Analysis, By Product Type (Unfractionated Heparin (UFH), and Low Molecular Weight Heparin (LMWH)), By Source (Bovine, and Porcine) , By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and Others), By Route of Administration (Intravenous Infusion, and Subcutaneous Injection), By End User (Hospitals & ASCs, Clinics, and Others), and Regional Forecast, 2020-2027. ”The market size stood at USD 8.39 billion in 2019.

For more information visit: https://www.fortunebusinessinsights.com/heparin-market-104447

Major Heparin Market Key players covered in the report include:

Opocrin SpA (Formigine, Italy)
Baxter (Deerfield, US)
Pfizer Inc. (New York, US)
Bioiberica SAU (Barcelona, ​​Spain)
Fresenius SE & Co. KGaA (Bad Homburg, Germany)
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Shijiazhuang, China)
Braun Melsungen AG (Melsungen, Germany)
Reddy's Laboratories Ltd. (Hyderabad, India)
LEO Pharma A / S (Ballerup, Denmark)
Aspen Holdings (Durban, South Africa)
Other Players
Rising Incidence of Chronic Disorders to Incite Business Development

The increasing prevalence of cardiovascular diseases around the world, including heart attacks and strokes will spur opportunities for the market. As per the American Heart Association (AHA) Heart Disease and Stroke Statistics, an estimated 5.3 million Americans suffered from atrial fibrillation in 2019. The As per the Centers for Disease Control and Prevention, coronary heart disease is the most common type of heart disease, killing 365,914 people in 2017.4. About 18.2 million adults age 20 and older have CAD (about 6.7%). Moreover, 2 in 10 deaths from CAD happen in adults less than 65 years old.The increasing awareness about the benefits of heparin in the treatment and management of heart diseases will improve the prospects of the market in the foreseeable future.

Minimal Impact on the Market During COVID-19

The limitations on non-essential medical procedures and consultations has had a drastic impact on the global market amid COVID-19. The healthcare industry has observed a decline in other medical services other coronavirus. The increased emphasis on COVID's vaccine has reduced the demand for other However, government initiatives, including heavy investments and free medical aid will influence the healthy growth of the market in the time of the pandemic.